<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:06:01Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5571515" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5571515</identifier><datestamp>2017-09-01</datestamp><setSpec>jcmmopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id>
      <journal-id journal-id-type="publisher-id">JCMM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Cellular and Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1582-1838</issn>
      <issn pub-type="epub">1582-4934</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5571515</article-id>
      <article-id pub-id-type="pmcid">PMC5571515</article-id>
      <article-id pub-id-type="pmc-uid">5571515</article-id>
      <article-id pub-id-type="pmid">28296156</article-id>
      <article-id pub-id-type="doi">10.1111/jcmm.13127</article-id>
      <article-id pub-id-type="publisher-id">JCMM13127</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>PAI1: a novel PP1âinteracting protein that mediates human plasma's antiâapoptotic effect in endothelial cells</article-title>
      </title-group>
      <contrib-group>
        <contrib id="jcmm13127-cr-0001" contrib-type="author">
          <name>
            <surname>Yao</surname>
            <given-names>Hui</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0002" contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Guangchun</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0003" contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Chao</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0004" contrib-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>Shichao</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0005" contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Lu</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0006" contrib-type="author">
          <name>
            <surname>Song</surname>
            <given-names>Liujiang</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0007" contrib-type="author">
          <name>
            <surname>Vijayan</surname>
            <given-names>K. Vinod</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0008" contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Qinglong</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="jcmm13127-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0009" contrib-type="author">
          <name>
            <surname>Xiong</surname>
            <given-names>Li</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0010" contrib-type="author">
          <name>
            <surname>Miao</surname>
            <given-names>Xiongying</given-names>
          </name>
          <xref ref-type="aff" rid="jcmm13127-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="jcmm13127-cr-0011" contrib-type="author" corresp="yes">
          <name>
            <surname>Deng</surname>
            <given-names>Xiyun</given-names>
          </name>
          <address>
            <email>dengxiyunmed@hunnu.edu.cn</email>
            <email>deng_xiyun@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="jcmm13127-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="jcmm13127-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<institution>Hunan Normal University Medical College</institution>
<named-content content-type="city">Changsha</named-content>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">China</country>
</aff>
      <aff id="jcmm13127-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>Hunan Normal University Medical College</institution>
<named-content content-type="city">Changsha</named-content>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">China</country>
</aff>
      <aff id="jcmm13127-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Baylor College of Medicine and Center for Translational Research on Inflammatory Diseases (CTRID)</named-content>
<institution>Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)</institution>
<named-content content-type="city">Houston</named-content>
<named-content content-type="country-part">TX</named-content>
<country country="US">USA</country>
</aff>
      <aff id="jcmm13127-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Surgery</named-content>
<institution>University of Pittsburgh Medical Center</institution>
<named-content content-type="city">Pittsburgh</named-content>
<named-content content-type="country-part">PA</named-content>
<country country="US">USA</country>
</aff>
      <aff id="jcmm13127-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of General Surgery</named-content>
<named-content content-type="organisation-division">Second Xiangya Hospital</named-content>
<institution>Central South University</institution>
<named-content content-type="city">Changsha</named-content>
<named-content content-type="country-part">Hunan</named-content>
<country country="CN">China</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Xiyun DENG, Ph.D.<break/>
Eâmail: <email>dengxiyunmed@hunnu.edu.cn</email> or <email>deng_xiyun@hotmail.com</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <volume>21</volume>
      <issue>9</issue>
      <issue-id pub-id-type="doi">10.1111/jcmm.2017.21.issue-9</issue-id>
      <fpage>2068</fpage>
      <lpage>2076</lpage>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCMM-21-2068.pdf"/>
      <abstract id="jcmm13127-abs-0001">
        <title>Abstract</title>
        <p>Activation of apoptotic signalling in endothelial cells contributes to the detrimental effects of a variety of pathological stimuli. In investigating the molecular events underlying the antiâapoptotic effect of human plasma in cultured human endothelial cells, we unexpectedly uncovered a novel mechanism of apoptosis suppression by human plasma through an interaction between two previously unrelated proteins. Human plasma inhibited hypoxiaâserum deprivationâinduced apoptosis and stimulated BAD<sup>S136</sup> and Akt<sup>S473</sup> phosphorylation. Akt1 silencing reversed part (~52%) of the antiâapoptotic effect of human plasma, suggesting the existence of additional mechanisms mediating the antiâapoptotic effect other than Akt signalling. Human plasma disrupted the interaction of BAD with protein phosphatase 1 (PP1). Mass spectrometry identified fourteen PP1âinteracting proteins induced by human plasma. Notably, a group of serine protease inhibitors including plasminogen activator inhibitor 1 (PAI1), a major inhibitor of fibrinolysis, were involved. Silencing of PAI1 attenuated the antiâapoptotic effect of human plasma. Furthermore, combined Akt1 and PAI1 silencing attenuated the majority of the antiâapoptotic effect of human plasma. We conclude that human plasma protects against endothelial cell apoptosis through sustained BAD phosphorylation, which is achieved by, at least in part, a novel interaction between PP1 with PAI1.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="jcmm13127-kwd-0001">plasminogen activator inhibitor 1</kwd>
        <kwd id="jcmm13127-kwd-0002">protein phosphatase 1</kwd>
        <kwd id="jcmm13127-kwd-0003">PP1âinteracting protein</kwd>
        <kwd id="jcmm13127-kwd-0004">apoptosis</kwd>
        <kwd id="jcmm13127-kwd-0005">endothelial cells</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>National Natural Science Foundation of China</funding-source>
          <award-id>81472496</award-id>
          <award-id>81372628</award-id>
        </award-group>
        <award-group>
          <funding-source>US National Institutes of Health</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="1"/>
        <page-count count="9"/>
        <word-count count="5842"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>jcmm13127</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>September 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.8 mode:remove_FC converted:25.08.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group id="jcmm13127-ntgp-0001">
        <fn fn-type="equal" id="jcmm13127-note-1001">
          <p>HY and GH contributed equally to this work.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="jcmm13127-sec-0001">
      <title>Introduction</title>
      <p>Normal organ function relies upon the maintenance of vascular homeostasis and the integrity of the endothelial lining of blood vessels. Endothelial cell (EC) survival/apoptosis plays important roles in the homeostasis of the vascular system. EC apoptosis is known to alter cell morphology by interrupting the cellâcell and cellâmatrix interaction, resulting in eventual removal of ECs from their underlying basement membrane. Therefore, anomalous EC apoptosis is considered a critical step that provokes acute endothelial dysfunction and plays an important role in the development of numerous disease conditions such as atherosclerosis and chronic transplant vasculopathy <xref rid="jcmm13127-bib-0001" ref-type="ref">1</xref>, <xref rid="jcmm13127-bib-0002" ref-type="ref">2</xref>. Our body system possesses a wellâdeveloped mechanism of maintaining vascular homeostasis through the prevention of EC injury caused by abnormally increased apoptosis.</p>
      <p>Members of the Bclâ2 family are key regulators of apoptosis that include both antiâapoptotic and proâapoptotic proteins <xref rid="jcmm13127-bib-0003" ref-type="ref">3</xref>. The proâapoptotic BH3âonly protein BAD plays a critical role in the regulation of EC apoptosis <italic>in vivo</italic> and <italic>in vitro</italic>
<xref rid="jcmm13127-bib-0004" ref-type="ref">4</xref>. In its unphosphorylated form, BAD triggers the release of mitochondrial apoptogenic factors into the cytoplasm, leading to loss of mitochondrial functions and subsequent caspase activation. Phosphorylation of BAD by protein kinases such as PKB/Akt and PKA results in binding of BAD to 14â3â3 proteins <xref rid="jcmm13127-bib-0005" ref-type="ref">5</xref>. The binding of BAD to 14â3â3 displaces BAD from complexing with its antiâapoptotic partners, such as BclâxL, and blocks the ability of BAD to induce cell death, thus promoting cell survival <xref rid="jcmm13127-bib-0006" ref-type="ref">6</xref>. On the contrary, dephosphorylation of BAD by protein phosphatases (PPs) results in dissociation of BAD from 14â3â3, translocation to the mitochondria and subsequent association with the antiâapoptotic protein BclâxL, thus promoting apoptosis <xref rid="jcmm13127-bib-0005" ref-type="ref">5</xref>.</p>
      <p>In this study, we investigated the antiâapoptotic effect of human plasma (HP) and the underlying molecular mechanisms using an <italic>in vitro</italic> model of EC injury. We found that HP suppressed EC apoptosis, at least partly, <italic>via</italic> the stimulation of phosphorylation of the proâapoptotic protein BAD. Through liquid chromatographyâtandem mass spectrometry (LCâMS/MS), coâimmunoprecipitation and glutathione <italic>S</italic>âtransferase (GST) pullâdown assay, we identified PAI1 as a novel PP1âinteracting protein (PIPs), which plays an important role in HPâmediated BAD phosphorylation and antiâapoptotic effect in ECs.</p>
    </sec>
    <sec id="jcmm13127-sec-0002">
      <title>Materials and methods</title>
      <sec id="jcmm13127-sec-0003">
        <title>Reagents and antibodies</title>
        <p>Antibodies against phosphoâAkt (Ser473) and phosphoâBAD (Ser136) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against BAD, 14â3â3, Akt, PP1 (recognizing all isoforms), GAPDH and an isotypeâmatched IgG control for immunoprecipitation were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). AntiâPAI1 antibody was purchased from BD Transduction Laboratories (Sparks, MD, USA). The siRNAs against Akt1, PAI1 (SERPIN E1) and the nonâtargeting mock siRNA were purchased from Dharmacon (Waltham, MA, USA). Lipofectamine 2000, Dynabeads Protein G and foetal bovine serum (FBS) were obtained from Life Technologies (Carlsbad, CA, USA). HP was obtained by routine plasma separation technique under aseptic conditions from healthy donors.</p>
      </sec>
      <sec id="jcmm13127-sec-0004">
        <title>Cell culture and experimental treatments</title>
        <p>Human pulmonary microvascular ECs (HPMECs) and human cardiac microvascular ECs (HCMECs) were purchased from PromoCell (Heidelberg, Germany). These cells were routinely cultured in EC growth medium MV2 containing 10% FBS supplemented with the respective growth supplement pack as recommended by the manufacturer. Both cell types were tested negative for mycoplasma and were used within passage 10 for all experiments. For normoxic culture, the cells were incubated in a 37Â°C incubator with 21% O<sub>2</sub> and 5% CO<sub>2</sub>. Hypoxia (1% O<sub>2</sub> and 5% CO<sub>2</sub>) was achieved in a hypoxia chamber (Thermo Fisher Scientific, Waltham, MA, USA) through injecting N<sub>2</sub> gas.</p>
        <p>Two protocols of hypoxiaâreoxygenation (HR) <xref rid="jcmm13127-bib-0007" ref-type="ref">7</xref>, <xref rid="jcmm13127-bib-0008" ref-type="ref">8</xref> and serum starvation (SS) of cell treatment were employed. For apoptosis analysis, the cells seeded in 96âwell plates (1.2 Ã 10<sup>4</sup> cells/well) were allowed to adhere overnight before the HR/SS procedure. To induce apoptosis, the cells were cultured in starvation medium containing 0.1% FBS under hypoxia (1% O<sub>2</sub>) for 24 hrs followed by treatment with various concentrations of HP for another 24 hrs under normoxia (21% O<sub>2</sub>) (Fig. <xref rid="jcmm13127-fig-0001" ref-type="fig">1</xref> Scheme A). For all other experiments, the cells seeded in 6âcm dishes (2.5 Ã 10<sup>5</sup> cells/dish) were grown overnight in regular culture medium containing 10% FBS under normoxia. To induce signalling changes, the cells were changed to medium containing 0.1% FBS and starved under hypoxia for 4 hrs. HP was added at the end of starvation and the treatment continued for 30 min. under hypoxia (Fig. <xref rid="jcmm13127-fig-0001" ref-type="fig">1</xref> Scheme B). For both schemes, to keep the total volume constant after HP addition, the corresponding volume of the culture medium was removed before the same amount of HP added to each treatment group.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>The HR/SS cell treatment protocols. Two protocols of hypoxiaâreoxygenation (HR) and serum starvation (SS) were employed for the treatment of cells. Scheme A, after seeding, the cells were cultured in starvation medium (containing 0.1% FBS) under hypoxia (1% O<sub>2</sub>) for 24 hrs followed by treatment with HP for 24 hrs under normoxia (21% O<sub>2</sub>). Scheme B, after seeding, the cells were cultured in starvation medium (containing 0.1% FBS) under hypoxia (1% O<sub>2</sub>) for 4 hrs followed by treatment with HP for 30 min. under normoxia (21% O<sub>2</sub>). Scheme A and Scheme B are used for cell apoptosis and signalling studies, respectively.</p>
          </caption>
          <graphic id="nlm-graphic-1" xlink:href="JCMM-21-2068-g001"/>
        </fig>
      </sec>
      <sec id="jcmm13127-sec-0005">
        <title>Apoptosis analysis</title>
        <p>To induce apoptosis, we used a HR/SS protocol as described in Figure <xref rid="jcmm13127-fig-0001" ref-type="fig">1</xref> Scheme A. After culture in regular culture conditions for 24 hrs, the cells were serumâstarved with medium containing 0.1% FBS under hypoxia for 24 hrs (1% O<sub>2</sub>). HP was added at the beginning of reoxygenation (21% O<sub>2</sub>). At the end of the experimental procedure, the same volume (50 Î¼l from each well) of conditioned media was collected and used for caspaseâ3/7 activity assay using a luminescent CaspaseâGlo 3/7 Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. At the same time, the cells were lysed and used for the detection of fragmented nucleosomes using a Cell Death Detection kit (Roche, Indianapolis, IN, USA) as described <xref rid="jcmm13127-bib-0009" ref-type="ref">9</xref>.</p>
      </sec>
      <sec id="jcmm13127-sec-0006">
        <title>siRNAâmediated gene silencing</title>
        <p>ECs (1.2 Ã 10<sup>5</sup> cells/6âcm dish) were transfected with siRNA against Aktl, PAI1 or a scramble mock siRNA at a final concentration of 100 nM using Lipofectamine 2000 as recommended by the manufacturer. Seventyâtwo hours after transfection, the cells were subjected to the HR/SS procedure and treated with HP followed by wholeâcell lysate preparation and immunoblotting according to the procedure described in Figure <xref rid="jcmm13127-fig-0001" ref-type="fig">1</xref> Scheme B.</p>
      </sec>
      <sec id="jcmm13127-sec-0007">
        <title>Coâimmunoprecipitation, gel staining and immunoblotting</title>
        <p>Wholeâcell lysates were prepared from cultured cells using 1 Ã cell lysis buffer (Cell Signaling Technology) with 1 Ã protease inhibitor cocktail (Complete Mini, Roche) and 1 mM PMSF (SigmaâAldrich, St Louis, MO, USA) added. For coâimmunoprecipitation, 100 Î¼g of wholeâcell lysate was immunoprecipitated with 0.2 Î¼g of an antibody against BAD, PP1 or isotypeâmatched control IgG for 1 hr at 4Â°C followed by overnight incubation with 20 Î¼l of washed Dynabeads Protein G (Life Technologies) at 4Â°C. Bound proteins were washed three times with PBS containing 0.02% Tweenâ20 and eluted with 1.5 Ã sample buffer containing 50 mM DTT (Life Technologies). After boiling, an equal volume of each immunoprecipitation sample or wholeâcell lysate was separated on a 4â12% gradient density NuPAGE Novex BisâTris precast denaturing gel (Life Technologies). The separated proteins were subjected to either silver staining or immunoblotting and ECL development according to our standard protocol <xref rid="jcmm13127-bib-0010" ref-type="ref">10</xref>. For quantification of immunoblot bands, the grey scale densities were obtained using the LIâCOR Image Studio Digits Software V3.1 (Lincoln, NE, USA) and the relative intensities calculated by normalizing against the loading control from at least two independent experiments.</p>
      </sec>
      <sec id="jcmm13127-sec-0008">
        <title>MS analysis and database searching</title>
        <p>Gel bands from control and treated cells were excised, and inâgel digestion was performed. The tryptic digests were taken to dryness in a Thermo SpeedVac and dissolved in 20 Î¼l of 2% acetonitrile and 0.1% formic acid in water (Solvent A). Samples were analysed on a LTQ Orbitrap XL (Thermo Fisher Scientific) interfaced with an Eksigent nanoâLC 2D plus ChipLC system (Eksigent Technologies, Dublin, CA, USA). Reversedâphase C18 chromatographic separation of peptides was carried out on a ChromXP C18âCL column (75 Î¼m i.d. Ã 10 cm length, 3 Î¼m) at 300 nl/min., with column temperature controlled at 60Â°C. Gradient conditions were as follows: 3â8% Solvent B (0.1% formic acid in acetonitrile) for 5 min.; 8â33% Solvent B for 120 min.; 33â90% Solvent B for 10 min.; 90% Solvent B held for 10 min.; 90â3% for 5 min. The total run time was 150 min. Data analysis was performed with MaxQuant software, supported by Mascot (version 3.2.02) as a database search engine for peptide identification using following criteria: database: human SwissProt; enzyme: trypsin; miscleavage: 2; MS tolerance: 10 ppm; MS/MS tolerance: 0.8 Da; fixed modifications: carbamidomethylation; variable modifications: oxidation (M).</p>
      </sec>
      <sec id="jcmm13127-sec-0009">
        <title>Construction of PP1âGST fusion proteins and GST pullâdown</title>
        <p>Four PP1 isoforms, <italic>that is</italic> PP1Î±, PP1Î², PP1Î³1 and PP1Î³2, the latter two arising from the same gene through alternative splicing, have been identified with near 90% amino acid sequence identity <xref rid="jcmm13127-bib-0011" ref-type="ref">11</xref>. The cDNAs for PP1Î±, PP1Î² and PP1Î³1 in pCMV vector were amplified by PCR and subcloned into a GST vector pGEX 4Tâ1 (GE Heathcare Biosciences, Piscataway, NJ, USA). GSTâtagged PP1Î±, PP1Î², PP1Î³1 proteins and control GST protein were expressed in <italic>E</italic>. <italic>Coli</italic> following induction with isopropylâÎ²âDâthiogalactopyranoside (IPTG) and purified using glutathioneâsepharose beads (GE Healthcare, Pittsburgh, PA, USA) <xref rid="jcmm13127-bib-0012" ref-type="ref">12</xref>. Standard GST pullâdown assay was performed as previously described <xref rid="jcmm13127-bib-0013" ref-type="ref">13</xref>. After pullâdown, the proteins were eluted with 1.5 Ã sample buffer containing 50 mM DTT and resolved by 4â12% BisâTris denaturing gel electrophoresis followed by immunoblotting as described above.</p>
      </sec>
      <sec id="jcmm13127-sec-0010">
        <title>Statistical analysis</title>
        <p>All quantitative values were presented as mean Â± S.D. from at least two independent experiments. Oneâway <sc>anova</sc> was used for multiple group comparisons of means followed by the HolmâSidak <italic>post hoc</italic> test using SigmaPlot 12.5. <italic>P</italic> &lt; 0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="jcmm13127-sec-0011">
      <title>Results</title>
      <sec id="jcmm13127-sec-0012">
        <title>Human plasma protects against EC apoptosis</title>
        <p>To determine whether HP has a protective effect against EC apoptosis under a culture condition that induces cell injury, we used an <italic>in vitro</italic> EC model of HR/SS (Fig. <xref rid="jcmm13127-fig-0001" ref-type="fig">1</xref> Scheme A) to induce EC apoptosis. The apoptosis induced by HR/SS was indeed inhibited by HP as demonstrated by doseâdependent inhibition of DNA fragmentation (Fig. <xref rid="jcmm13127-fig-0002" ref-type="fig">2</xref>A) and caspase 3/7 activity (Fig. <xref rid="jcmm13127-fig-0002" ref-type="fig">2</xref>B) in HPMECs.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Human plasma protects endothelial cells against hypoxiaâreoxygenation and serum starvationâinduced apoptosis. HPMECs were cultured and treated for 24 hrs with various concentrations of HP according to the procedure described in Scheme A. The HR/SS (â) control cells were cultured under normoxia and without serum starvation during the whole procedure. At the end of the experiment, the cells were lysed and subjected to detection of DNA fragmentation using the Cell Death Detection kit (<bold>A</bold>). Alternatively, conditioned media were collected at the end of the experiment and subjected to caspase 3/7 activity analysis using the CaspaseâGlo 3/7 Assay kit (<bold>B</bold>). Values were mean Â± S.E.M. from three independent experiments. Different symbols indicate <italic>P</italic> &lt; 0.05 between the groups; identical symbols indicate no significant difference. Note: Different lowerâcase letters denote significant statistical difference (<italic>P</italic> &lt; 0.05) among different groups. HR: hypoxiaâreoxygenation; SS: serum starvation; RLUs: relative light units.</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="JCMM-21-2068-g002"/>
        </fig>
      </sec>
      <sec id="jcmm13127-sec-0013">
        <title>Human plasma maintains BAD phosphorylation by activating Akt and preventing the interaction of PP1 with BAD</title>
        <p>Given the fact that the maintenance of BAD phosphorylation plays a central role in the inhibition of apoptosis in ECs <italic>in vivo</italic> and <italic>in vitro</italic>
<xref rid="jcmm13127-bib-0004" ref-type="ref">4</xref>, we asked whether inhibition of EC apoptosis by HP was related to the change of the phosphorylation status of BAD. As expected, when used at concentrations ranging from 10% to 50%, HP indeed induced doseâdependent phosphorylation of BAD at Ser136 in both HPMECs and HCMECs (Fig. <xref rid="jcmm13127-fig-0003" ref-type="fig">3</xref>). Phosphorylation of BAD was also upâregulated by HP at another critical site, Ser112 (data not shown). In support of the antiâapoptotic role of phosphorylated BAD, HP increased interaction of BAD with 14â3â3 proteins in both cell types. Increased interaction between BAD and 14â3â3 is supposed to result in decreased binding of BAD to BclâxL <xref rid="jcmm13127-bib-0006" ref-type="ref">6</xref>. We examined this possibility in the case of HP treatment in ECs. However, for unknown reasons, we did not observe a decrease in the binding of BAD to BclâxL upon HP treatment in both EC types (Fig. <xref rid="jcmm13127-fig-0003" ref-type="fig">3</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Human plasma induces phosphorylation of BAD and increases its interaction with 14â3â3 in endothelial cells. ECs were treated for 30 min. with HP at the indicated concentrations according to the procedure described in Scheme B and subjected to wholeâcell lysate preparation followed by immunoblotting or immunoprecipitationâimmunoblotting. IP: immunoprecipitation; IB: immunoblotting; WCL: wholeâcell lysate.</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="JCMM-21-2068-g003"/>
        </fig>
        <p>Next, we investigated the upstream kinases that are involved in HPâmediated BAD phosphorylation. Two major kinases, PKB/Akt and PKA, are involved in multipleâsite phosphorylation of BAD <xref rid="jcmm13127-bib-0005" ref-type="ref">5</xref>. As depicted in Figure <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>A, we observed a doseâdependent increase in phosphorylation of Akt at Ser473 in both HPMECs and HCMECs. HP also upâregulated the phosphorylation of the catalytic subunit of PKA (Thr197) but at a much lower level (data not shown), suggesting that Akt plays a much more important role in HPâinduced BAD phosphorylation.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Akt is partially responsible for the antiâapoptotic effect of human plasma. ECs were treated according to Scheme A (4<bold>C</bold> and 4<bold>D</bold>) or Scheme B (4<bold>A</bold> and 4<bold>B</bold>). (<bold>A</bold>) ECs treated with different concentrations of HP were subjected to wholeâcell lysate preparation and immunoblotting. (<bold>B</bold>â<bold>D</bold>), HPMECs were transfected with Akt1 siRNA or a scramble nonâtargeting control siRNA using Lipofectamine 2000. Seventyâtwo hours after transfection, the cells were starved and treated for 30 min. with or without HP (30%) followed by immunoblotting (<bold>B</bold>), or subjected to DNA fragmentation (<bold>C</bold>), or caspase 3/7 activity assay (<bold>D</bold>). Note: Different lowerâcase letters denote significant statistical difference (<italic>P</italic> &lt; 0.05) among different groups. IB: immunoblotting; RLUs: relative light units.</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="JCMM-21-2068-g004"/>
        </fig>
        <p>The role of Akt in HPâmediated BAD phosphorylation and apoptosis inhibition was investigated by genetic manipulation. We knocked down Akt1, which is the major Akt isoform in ECs <xref rid="jcmm13127-bib-0014" ref-type="ref">14</xref>, by siRNAâmediated gene silencing. As shown in Figure <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>B, knockdown of Akt1 resulted in a decrease in Akt level by 79.1 Â± 2.0% and a decrease in HPâinduced BAD phosphorylation at Ser136 (62.3 Â± 4.6%) in HPMECs. As expected, Akt1 silencing also reversed HP's inhibition of DNA fragmentation (51.8 Â± 8.1%) (Fig. <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>C) and caspase 3/7 activity (53.5 Â± 4.0%) (Fig. <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>D).</p>
        <p>As Akt silencing only partially reversed HP's antiâapoptotic effect (Fig. <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>C and D), the participation of other antiâapoptotic mechanisms was also investigated. PPs, specifically PP1 and PP2B, dephosphorylate BAD at Ser136 and switch BAD from being antiâapoptotic to proâapoptotic <xref rid="jcmm13127-bib-0005" ref-type="ref">5</xref>. As PP1 catalyses the majority of protein dephosphorylation reactions in eukaryotic cells <xref rid="jcmm13127-bib-0015" ref-type="ref">15</xref>, we tested whether PP1 is also involved in HPâmediated BAD phosphorylation in the scenario of EC injury. HP doseâdependently decreased the interaction of PP1 with BAD in both HPMECs and HCMECs (Fig. <xref rid="jcmm13127-fig-0005" ref-type="fig">5</xref>). Dissociation of PP1 from BAD prevents the dephosphorylation of BAD by PP1, thereby maintaining BAD in a hyperphosphorylated antiâapoptotic state in conjugation with HPâinduced Akt activation.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Human plasma decreases the interaction of PP1 with BAD in endothelial cells. ECs treated with different concentrations of HP according to Scheme B were subjected to immunoprecipitationâimmunoblotting. IP: immunoprecipitation; IB: immunoblotting; WCL: wholeâcell lysate.</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="JCMM-21-2068-g005"/>
        </fig>
      </sec>
      <sec id="jcmm13127-sec-0014">
        <title>Identification of PAI1 as a PP1âinteracting protein</title>
        <p>In search for the novel antiâapoptotic mechanisms involved in EC protection, we employed LCâMS/MS, coâimmunoprecipitation and GST pullâdown assays in an attempt to identify PIPs that are important for HP's protective effects in ECs. HCMECs were treated with or without HP and subjected to immunoprecipitation with an antiâPP1 antibody. The proteins that were pulled down with the antiâPP1 antibody were separated by SDSâPAGE and visualized by silver staining. One PP1âinteracting band around 37â50 kD (Band X) was consistently present in HPâtreated HCMECs in repeated experiments (Fig. <xref rid="jcmm13127-fig-0006" ref-type="fig">6</xref>A). This Band X was excised and subjected to tryptic digestion and LCâMS/MS. Through database search, 14 PIPs induced by HP were identified (Table <xref rid="jcmm13127-tbl-0001" ref-type="table-wrap">1</xref>). Of particular interest were a group of serine protease inhibitors, such as PAI1, serine protease inhibitor 2 and serine protease inhibitor B9, demonstrating the importance of this group of proteins in the interaction with PP1.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Identification of PAI1 as a PP1âinteracting protein. (<bold>A</bold>) HCMECs were treated with or without HP for 30 min. according to Scheme B and wholeâcell lysates subjected to immunoprecipitation using an antiâPP1 antibody followed by SDSâPAGE separation and silver staining. The positions of molecular mass markers are marked on the left. Band X is the gel band of interest which was subjected to LCâMS/MS analysis. (<bold>B</bold>) HCMECs were treated with HP for 30 min. and wholeâcell lysates were prepared and subjected to immunoprecipitationâimmunoblotting. (<bold>C</bold>) Wholeâcell lysates prepared from HCMECs treated with or without HP were incubated with an equal molar amount of GSTâtagged PP1 isoforms followed by pullâdown with glutathioneâsepharose beads. The eluted proteins were resolved by SDSâPAGE followed by immunoblotting. Ig, immunoglobulin; IP, immunoprecipitation; IB: immunoblotting; WCL: wholeâcell lysate.</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="JCMM-21-2068-g006"/>
        </fig>
        <table-wrap id="jcmm13127-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Identification of HPâinduced PP1âinteracting proteins in endothelial cells</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">No</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Eâvalue</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Protein name</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Protein description</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Protein function</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Accession Number</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">1</td>
                <td align="left" rowspan="1" colspan="1">2.20Eâ05</td>
                <td align="left" rowspan="1" colspan="1">PAI1</td>
                <td align="left" rowspan="1" colspan="1">Plasminogen activator inhibitor 1 (serine protease inhibitor E1)</td>
                <td align="left" rowspan="1" colspan="1">Serine protease inhibitor</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P05121">P05121</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">2</td>
                <td align="left" rowspan="1" colspan="1">2.50Eâ05</td>
                <td align="left" rowspan="1" colspan="1">DJB11</td>
                <td align="left" rowspan="1" colspan="1">DnaJ homolog subfamily B member 11</td>
                <td align="left" rowspan="1" colspan="1">Heatâshock protein binding</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q9UBS4">Q9UBS4</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">3</td>
                <td align="left" rowspan="1" colspan="1">2.20Eâ05</td>
                <td align="left" rowspan="1" colspan="1">SPI2</td>
                <td align="left" rowspan="1" colspan="1">Serine protease inhibitor 2</td>
                <td align="left" rowspan="1" colspan="1">Serine protease inhibitor</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P33830">P33830</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">4</td>
                <td align="left" rowspan="1" colspan="1">1.70Eâ03</td>
                <td align="left" rowspan="1" colspan="1">ANM2</td>
                <td align="left" rowspan="1" colspan="1">Protein arginine Nâmethyltransferase 2</td>
                <td align="left" rowspan="1" colspan="1">Arginine methyltransferase</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P55345">P55345</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">5</td>
                <td align="left" rowspan="1" colspan="1">1.90Eâ07</td>
                <td align="left" rowspan="1" colspan="1">ILF2</td>
                <td align="left" rowspan="1" colspan="1">Interleukin enhancerâbinding factor 2</td>
                <td align="left" rowspan="1" colspan="1">Transcriptional activator</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q12905">Q12905</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">6</td>
                <td align="left" rowspan="1" colspan="1">4.90Eâ04</td>
                <td align="left" rowspan="1" colspan="1">GNAT2</td>
                <td align="left" rowspan="1" colspan="1">Guanine nucleotideâbinding protein G(t) subunit alphaâ2</td>
                <td align="left" rowspan="1" colspan="1">Guanine nucleotideâbinding proteins (G proteins)</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P19087">P19087</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">7</td>
                <td align="left" rowspan="1" colspan="1">2.50Eâ03</td>
                <td align="left" rowspan="1" colspan="1">SERPINB9</td>
                <td align="left" rowspan="1" colspan="1">Serine protease inhibitor B9</td>
                <td align="left" rowspan="1" colspan="1">Serine protease inhibitor</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P50453">P50453</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">8</td>
                <td align="left" rowspan="1" colspan="1">8.50Eâ04</td>
                <td align="left" rowspan="1" colspan="1">ADRM1</td>
                <td align="left" rowspan="1" colspan="1">Proteasomal ubiquitin receptor ADRM1</td>
                <td align="left" rowspan="1" colspan="1">Proteasomal ubiquitin receptor</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q16186">Q16186</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">9</td>
                <td align="left" rowspan="1" colspan="1">1.60Eâ03</td>
                <td align="left" rowspan="1" colspan="1">S1PR5</td>
                <td align="left" rowspan="1" colspan="1">Sphingosine 1âphosphate receptor 5</td>
                <td align="left" rowspan="1" colspan="1">Receptor for the lysosphingolipid sphingosine 1âphosphate (S1P)</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q9H228">Q9H228</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">10</td>
                <td align="left" rowspan="1" colspan="1">5.50Eâ04</td>
                <td align="left" rowspan="1" colspan="1">SIAS</td>
                <td align="left" rowspan="1" colspan="1">Sialic acid synthase</td>
                <td align="left" rowspan="1" colspan="1">Nâacetylneuraminate biosynthesis</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q9NR45">Q9NR45</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">11</td>
                <td align="left" rowspan="1" colspan="1">1.90Eâ02</td>
                <td align="left" rowspan="1" colspan="1">K1C19</td>
                <td align="left" rowspan="1" colspan="1">Keratin, type I cytoskeletal 19</td>
                <td align="left" rowspan="1" colspan="1">Organization of myofibers</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P08727">P08727</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">12</td>
                <td align="left" rowspan="1" colspan="1">8.30Eâ03</td>
                <td align="left" rowspan="1" colspan="1">ADRB3</td>
                <td align="left" rowspan="1" colspan="1">Betaâ3 adrenergic receptor, isoform CRA_b</td>
                <td align="left" rowspan="1" colspan="1">G proteinâcoupled receptor</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="A8KAG8">A8KAG8</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">13</td>
                <td align="left" rowspan="1" colspan="1">2.50Eâ03</td>
                <td align="left" rowspan="1" colspan="1">PGK1</td>
                <td align="left" rowspan="1" colspan="1">Phosphoglycerate kinase 1</td>
                <td align="left" rowspan="1" colspan="1">Gluconeogenesis; glycolysis</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="P00558">P00558</ext-link>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">14</td>
                <td align="left" rowspan="1" colspan="1">2.10Eâ02</td>
                <td align="left" rowspan="1" colspan="1">ADAM5</td>
                <td align="left" rowspan="1" colspan="1">Putative disintegrin and metalloproteinase domainâcontaining protein 5</td>
                <td align="left" rowspan="1" colspan="1">Metalloendopeptidase activity</td>
                <td align="left" rowspan="1" colspan="1">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="Q6NVV9">Q6NVV9</ext-link>
</td>
              </tr>
            </tbody>
          </table>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>Serine protease inhibitor 2 has previously been reported to be one of the PIPs in vertebrates <xref rid="jcmm13127-bib-0016" ref-type="ref">16</xref>. PAI1 (molecular weight of about 45â48 kD) is a fibrinolysisâregulatory protein with known apoptosisâregulatory activity in ECs <xref rid="jcmm13127-bib-0017" ref-type="ref">17</xref>. To our knowledge, the interaction between PAI1 and PP1 has not been previously reported. We thus investigated whether PAI1 is a novel intracellular PIP that protects against apoptosis in ECs. The interaction between PP1 and PAI1 was confirmed by coâimmunoprecipitation followed by immunoblotting in HCMECs (Fig. <xref rid="jcmm13127-fig-0006" ref-type="fig">6</xref>B). Unexpectedly, we found that treatment with HP, especially at a high concentration (50%), led to a decrease in total PAI1 protein level. The reason for this is not known and might be an interesting issue for further investigation.</p>
        <p>Four isoforms of PP1 (PP1Î±, Î², Î³1 and Î³2) have been identified in mammals thus far <xref rid="jcmm13127-bib-0011" ref-type="ref">11</xref>. To further confirm the PP1âPAI1 interaction and ascertain the specific isoform of PP1 engaged in PAI1 binding, we performed GST pullâdown assay using purified PP1âGST fusion proteins. The interaction of PAI1 was prominently noticed with PP1Î² (&gt;&gt;PP1Î± &gt;PP1Î³1) in HPâtreated HCMECs (Fig. <xref rid="jcmm13127-fig-0006" ref-type="fig">6</xref>C). Previous studies by others have demonstrated that it is the PP1Î±, not PP1Î², isoform that can be targeted to BAD by the Bclâ2 family proteins <xref rid="jcmm13127-bib-0018" ref-type="ref">18</xref>, <xref rid="jcmm13127-bib-0019" ref-type="ref">19</xref>, <xref rid="jcmm13127-bib-0020" ref-type="ref">20</xref>. The difference between our findings and these reports might be because of the prevalence of different PP1 isoforms in different tissue types involved. The significance of this isoformâspecific preference of PP1 interaction with PAI1 is not clear yet.</p>
      </sec>
      <sec id="jcmm13127-sec-0015">
        <title>Gene silencing of PAI1 suppresses BAD phosphorylation and promotes EC apoptosis</title>
        <p>Based on the above observations of the PP1âPAI1 interaction, we ascertained whether this interaction has a pathophysiological role in maintaining the antiâapoptotic signals. To this end, HCMECs were silenced for PAI1 by siRNA and analysed for DNA fragmentation and caspase 3/7 activity upon HP treatment. Knockdown of PAI1 by siRNA resulted in near complete elimination of total PAI1 and attenuated HPâinduced BAD<sup>S136</sup> phosphorylation by 82.7 Â± 3.5% (Fig. <xref rid="jcmm13127-fig-0007" ref-type="fig">7</xref>A). Furthermore, PAI1 silencing reversed HP's inhibition of DNA fragmentation by 43.0 Â± 1.5% and caspase 3/7 activity by 39.4 Â± 2.9% (Fig. <xref rid="jcmm13127-fig-0007" ref-type="fig">7</xref>B and C). These data suggest that HP induces BAD phosphorylation and promotes EC survival through promoting the interaction between PAI1 and PP1 and displacing PP1 from complexing with BAD.</p>
        <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <p>PAI1 is responsible for part of human plasmaâmediated BAD phosphorylation and apoptosis protection. ECs were transfected with PAI1 siRNA using Lipofectamine 2000 and subjected to immunoprecipitationâimmunoblotting (<bold>A</bold>), DNA fragmentation (<bold>B</bold>) or caspase 3/7 activity assay (<bold>C</bold>). Note: Different lowerâcase letters denote significant statistical difference (<italic>P</italic> &lt; 0.05) among different groups. IB, immunoblotting; WCL, wholeâcell lysate; RLUs, relative light units.</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="JCMM-21-2068-g007"/>
        </fig>
      </sec>
    </sec>
    <sec id="jcmm13127-sec-0016">
      <title>Discussion</title>
      <p>Increased EC apoptosis leads to the disruption of vascular integrity, contributing to the pathogenesis of a variety of pathological conditions, such as ischaemiaâreperfusion injury. As humans, we have developed a delicate system to maintain vascular stability through the prevention or repair of EC apoptosis. In the present study, using a model of HR combined with serum deprivation (SS), we have shown that HP significantly stimulated phosphorylation of BAD and inhibited HR/SSâinduced vascular EC apoptosis. The underlying signalling mechanisms involved elevation of Aktâmediated BAD phosphorylation in conjugation with displacement of PP1 from BAD, thereby preventing BAD dephosphorylation. More importantly, we have identified PAI1 as a novel PIP which is involved in HPâmediated antiâapoptosis in ECs. Together, activation of these two interdependent pathways results in elevated BAD phosphorylation and is responsible for HP's antiâapoptotic effect in ECs. A summary of the signalling pathways mediating HP's regulation of BAD phosphorylation and antiâapoptotic effect in ECs is depicted in Figure <xref rid="jcmm13127-fig-0008" ref-type="fig">8</xref>.</p>
      <fig fig-type="Figure" xml:lang="en" id="jcmm13127-fig-0008" orientation="portrait" position="float">
        <label>Figure 8</label>
        <caption>
          <p>Schematic representation of the role of PAI1âPP1 interaction in the regulation of BAD phosphorylation and the antiâapoptotic effect in endothelial cells. (<bold>A</bold>) Under stress conditions such as hypoxiaâreoxygenation and serum deprivation, PP1 binds to BAD, rendering BAD in an unphosphorylated state and the cell eventually undergoes apoptosis. (<bold>B</bold>) HP induces BAD phosphorylation and promotes EC survival through promoting the interaction between PAI1 and PP1 and displacing PP1 from complexing with BAD. Activation of Akt signalling also contributes to the phosphorylation of BAD in this process.</p>
        </caption>
        <graphic id="nlm-graphic-15" xlink:href="JCMM-21-2068-g008"/>
      </fig>
      <p>The phosphorylation status of BAD is a crucial regulator of cell survival and death. Two types of signals regulate the phosphorylation level of BAD, thus determining whether BAD serves as an antiâapoptotic or proâapoptotic protein. While the Aktâmediated pathway upâregulates BAD phosphorylation, the PAI1âregulated PP1âdependent pathway downâregulates it. In our study, we have demonstrated the importance of these two regulatory arms on BAD phosphorylation and cell survival through gene silencing experiments (Figs <xref rid="jcmm13127-fig-0004" ref-type="fig">4</xref>B and <xref rid="jcmm13127-fig-0007" ref-type="fig">7</xref>A). Nevertheless, we observed some residual antiâapoptotic activity when either Akt1 or PAI was knocked down. This could be due to the residual protein levels, especially in the case of Akt1 knockâdown, and the subsequent BAD phosphorylation. In addition, the plasma is known to contain thousands of proteins covering a myriad of physiological and pathological functions <xref rid="jcmm13127-bib-0021" ref-type="ref">21</xref>, <xref rid="jcmm13127-bib-0022" ref-type="ref">22</xref>. Therefore, the possibility of the involvement of other factors such as ILâ2 <xref rid="jcmm13127-bib-0020" ref-type="ref">20</xref> or ILâ3 <xref rid="jcmm13127-bib-0023" ref-type="ref">23</xref> that promote BAD phosphorylation could not be excluded. Alternatively, other survival signals in the plasma may activate, for example, the MAPKâMEK <xref rid="jcmm13127-bib-0024" ref-type="ref">24</xref> or STAT3 <xref rid="jcmm13127-bib-0025" ref-type="ref">25</xref> signalling pathway and promote cell survival even in the absence of BAD phosphorylation.</p>
      <p>PP1 belongs to the phosphoprotein phosphatase (PPP) superfamily of protein Ser/Thr phosphatases. The PP1 holoenzyme is composed of a catalytic subunit (commonly known as PP1) with various kinds of regulatory (or targeting) subunits. While the catalytic PP1 subunit determines the activity of the PP1 holoenzyme, the regulatory subunit determines substrate specificity and subcellular localization of PP1 <xref rid="jcmm13127-bib-0026" ref-type="ref">26</xref>. Identification of the soâcalled PIPs, the regulatory subunits of PP1, has been a challenging and exciting area of mammalian cell biology and molecular pharmacology <xref rid="jcmm13127-bib-0026" ref-type="ref">26</xref>, <xref rid="jcmm13127-bib-0027" ref-type="ref">27</xref>. Being much more tissue or subcellular compartment specific than the PPs, the PIPs provide better targets of therapeutic potential in cardiovascular diseases and cancer, thus limiting unnecessary toxic side effect and increasing specificity <xref rid="jcmm13127-bib-0011" ref-type="ref">11</xref>.</p>
      <p>PAI1 is a singleâchain glycoprotein that belongs to the superfamily of SERPINs. PAI1 is the primary and most specific fastâacting inhibitor of both the tissueâtype plasminogen activator (tâPA) and the urinaryâtype plasminogen activator (uâPA) <xref rid="jcmm13127-bib-0017" ref-type="ref">17</xref>. PAI1 is involved in the soâcalled vascular remodelling through complex regulation of a delicate balance between proliferation and apoptosis of vascular ECs and smooth muscle cells <xref rid="jcmm13127-bib-0028" ref-type="ref">28</xref>. With regard to apoptosis regulation, PAI1 can contextâdependently inhibit or promote cell apoptosis in ECs and smooth muscle cells <xref rid="jcmm13127-bib-0029" ref-type="ref">29</xref>, <xref rid="jcmm13127-bib-0030" ref-type="ref">30</xref>. Induced expression of exogenous PAI1 has been shown to inhibit prostate cancer growth though induction of tumour endothelial apoptosis, thus limiting angiogenesis <xref rid="jcmm13127-bib-0031" ref-type="ref">31</xref>. Furthermore, PAI1 protects ECs from Fas/FasLâmediated apoptosis, establishing PAI1 as a potential target for antiâangiogenic and antivascular therapies <xref rid="jcmm13127-bib-0032" ref-type="ref">32</xref>. These studies, together with ours, highlight the importance of PAI1 in vascular biology that in a broader sense involves cardiovascular complications and cancer development.</p>
      <p>In summary, our study reveals a novel mechanism by which HP protects ECs from HR/SSâinduced apoptosis. PAI1, through its interaction with PP1 and together with Akt signalling, renders BAD in a hyperphosphorylated state, which mediates the antiâapoptotic effect of HP in ECs. Identification of PAI1 as a novel PIP offers PAI1 a totally different mode of action, <italic>that is</italic>, through intracellular interaction with PP1 and regulation of BAD phosphorylation in ECs. The exact mechanisms by which PAI1 interacts with PP1 and how PAI1âregulated BAD phosphorylation impacts cellular functions other than apoptosis need to be further investigated. The PP1âdocking motif in PAI1, similar to the one found in most other PIPs (<italic>e.g</italic>. RVxF) <xref rid="jcmm13127-bib-0015" ref-type="ref">15</xref> but is absent in PAI1, needs to be identified. In addition, the specific factors in the plasma that are responsible for triggering PAI1âPP1 interaction need to be further identified. In a broader context, identification of PAI1 as a novel PIP will open up a new avenue for intracellular signalling study in vascular biology.</p>
    </sec>
    <sec id="jcmm13127-sec-0018">
      <title>Conflict of interest statement</title>
      <p>The authors confirm that there is no conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack id="jcmm13127-sec-0017">
      <title>Acknowledgements</title>
      <p>This study was supported by the National Natural Science Foundation of China (81472496 to X.D. and 81372628 to X.M.) and the US National Institutes of Health (HL081613 and GM112806 to K.V.V.).</p>
    </ack>
    <ref-list content-type="cited-references" id="jcmm13127-bibl-0001">
      <title>References</title>
      <ref id="jcmm13127-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0001">
<string-name>
<surname>Rennier</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>JY</given-names>
</string-name>. <article-title>The role of deathâassociated protein kinase (DAPK) in endothelial apoptosis under fluid shear stress</article-title>. <source>Life Sci</source>. <year>2013</year>; <volume>93</volume>: <fpage>194</fpage>â<lpage>200</lpage>.<pub-id pub-id-type="pmid">23806751</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0002">
<string-name>
<surname>Cailhier</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Laplante</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hebert</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms</article-title>. <source>Am J Transplant</source>. <year>2006</year>; <volume>6</volume>: <fpage>247</fpage>â<lpage>53</lpage>.<pub-id pub-id-type="pmid">16426308</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0003">
<string-name>
<surname>Martinou</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Youle</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Mitochondria in apoptosis: Bclâ2 family members and mitochondrial dynamics</article-title>. <source>Dev Cell</source>. <year>2011</year>; <volume>21</volume>: <fpage>92</fpage>â<lpage>101</lpage>.<pub-id pub-id-type="pmid">21763611</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0004">
<string-name>
<surname>Ohi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nishikawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tokairin</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Maintenance of Bad phosphorylation prevents apoptosis of rat hepatic sinusoidal endothelial cells <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Am J Pathol</source>. <year>2006</year>; <volume>168</volume>: <fpage>1097</fpage>â<lpage>106</lpage>.<pub-id pub-id-type="pmid">16565486</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0005">
<string-name>
<surname>Klumpp</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Krieglstein</surname>
<given-names>J</given-names>
</string-name>. <article-title>Serine/threonine protein phosphatases in apoptosis</article-title>. <source>Curr Opin Pharmacol</source>. <year>2002</year>; <volume>2</volume>: <fpage>458</fpage>â<lpage>62</lpage>.<pub-id pub-id-type="pmid">12127881</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0006">
<string-name>
<surname>Datta</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Katsov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic><article-title>14â3â3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation</article-title>. <source>Mol Cell</source>. <year>2000</year>; <volume>6</volume>: <fpage>41</fpage>â<lpage>51</lpage>.<pub-id pub-id-type="pmid">10949026</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0007">
<string-name>
<surname>TheradeâMatharan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Laemmel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Duranteau</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Reoxygenation after hypoxia and glucose depletion causes reactive oxygen species production by mitochondria in HUVEC</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2004</year>; <volume>287</volume>: <fpage>R1037</fpage>â<lpage>43</lpage>.<pub-id pub-id-type="pmid">15205181</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0008">
<string-name>
<surname>HaywoodâWatson</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Holcomb</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>EA</given-names>
</string-name>, <italic>et al</italic><article-title>Modulation of syndecanâ1 shedding after hemorrhagic shock and resuscitation</article-title>. <source>PLoS One</source>. <year>2011</year>; <volume>6</volume>: <fpage>e23530</fpage>.<pub-id pub-id-type="pmid">21886795</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0009">
<string-name>
<surname>Cao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic><article-title>Dietary fiber enhances TGFâbeta signaling and growth inhibition in the gut</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2011</year>; <volume>301</volume>: <fpage>G156</fpage>â<lpage>64</lpage>.<pub-id pub-id-type="pmid">21454444</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0010">
<string-name>
<surname>Yang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic><article-title>Effects of Lovastatin on MDAâMBâ231 Breast Cancer Cells: an antibody microarray analysis</article-title>. <source>J Cancer</source>. <year>2016</year>; <volume>7</volume>: <fpage>192</fpage>â<lpage>9</lpage>.<pub-id pub-id-type="pmid">26819643</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0011">
<string-name>
<surname>Fardilha</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Esteves</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>KorrodiâGregorio</surname>
<given-names>L</given-names>
</string-name>, <italic>et al</italic>
<article-title>The physiological relevance of protein phosphatase 1 and its interacting proteins to health and disease</article-title>. <source>Curr Med Chem</source>. <year>2010</year>; <volume>17</volume>: <fpage>3996</fpage>â<lpage>4017</lpage>.<pub-id pub-id-type="pmid">20939825</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0012">
<string-name>
<surname>Alrehani</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pradhan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Khatlani</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Distinct roles for the alpha, beta and gamma1 isoforms of protein phosphatase 1 in the outsideâin alphaIIbbeta3 integrin signallingâdependent functions</article-title>. <source>Thromb Haemost</source>. <year>2013</year>; <volume>109</volume>: <fpage>118</fpage>â<lpage>26</lpage>.<pub-id pub-id-type="pmid">23197154</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0013">
<string-name>
<surname>Doufexis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Storr</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>King</surname>
<given-names>PJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>Interaction of the melanocortin 2 receptor with nucleoporin 50: evidence for a novel pathway between a Gâproteinâcoupled receptor and the nucleus</article-title>. <source>FASEB J</source>. <year>2007</year>; <volume>21</volume>: <fpage>4095</fpage>â<lpage>100</lpage>.<pub-id pub-id-type="pmid">17625072</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0014">
<string-name>
<surname>Somanath</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Razorenova</surname>
<given-names>OV</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>Akt1 in endothelial cell and angiogenesis</article-title>. <source>Cell Cycle</source>. <year>2006</year>; <volume>5</volume>: <fpage>512</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">16552185</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0015">
<string-name>
<surname>Boens</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Szeker</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Van Eynde</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Interactorâguided dephosphorylation by protein phosphataseâ1</article-title>. <source>Methods Mol Biol</source>. <year>2013</year>; <volume>1053</volume>: <fpage>271</fpage>â<lpage>81</lpage>.<pub-id pub-id-type="pmid">23860659</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0016">
<string-name>
<surname>Hendrickx</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beullens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ceulemans</surname>
<given-names>H</given-names>
</string-name>, <italic>et al</italic><article-title>Docking motifâguided mapping of the interactome of protein phosphataseâ1</article-title>. <source>Chem Biol</source>. <year>2009</year>; <volume>16</volume>: <fpage>365</fpage>â<lpage>71</lpage>.<pub-id pub-id-type="pmid">19389623</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0017">
<string-name>
<surname>Cesari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pahor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Incalzi</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Plasminogen activator inhibitorâ1 (PAIâ1): a key factor linking fibrinolysis and ageârelated subclinical and clinical conditions</article-title>. <source>Cardiovasc Ther</source>. <year>2010</year>; <volume>28</volume>: <fpage>e72</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">20626406</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0018">
<string-name>
<surname>Ayllon</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cayla</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic><article-title>Bclâ2 targets protein phosphatase 1 alpha to Bad</article-title>. <source>J Immunol</source>. <year>2001</year>; <volume>166</volume>: <fpage>7345</fpage>â<lpage>52</lpage>.<pub-id pub-id-type="pmid">11390485</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0019">
<string-name>
<surname>Ayllon</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cayla</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>The antiâapoptotic molecules BclâxL and Bclâw target protein phosphatase 1alpha to Bad</article-title>. <source>Eur J Immunol</source>. <year>2002</year>; <volume>32</volume>: <fpage>1847</fpage>â<lpage>55</lpage>.<pub-id pub-id-type="pmid">12115603</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0020">
<string-name>
<surname>Ayllon</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>A</given-names>
</string-name>, <italic>et al</italic>
<article-title>Protein phosphatase 1alpha is a Rasâactivated Bad phosphatase that regulates interleukinâ2 deprivationâinduced apoptosis</article-title>. <source>EMBO J</source>. <year>2000</year>; <volume>19</volume>: <fpage>2237</fpage>â<lpage>46</lpage>.<pub-id pub-id-type="pmid">10811615</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0021">
<string-name>
<surname>Muthusamy</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hanumanthu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Suresh</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic><article-title>Plasma Proteome Database as a resource for proteomics research</article-title>. <source>Proteomics</source>. <year>2005</year>; <volume>5</volume>: <fpage>3531</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">16041672</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0022">
<string-name>
<surname>Anderson</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>NG</given-names>
</string-name>. <article-title>The human plasma proteome: history, character, and diagnostic prospects</article-title>. <source>Mol Cell Proteomics</source>. <year>2002</year>; <volume>1</volume>: <fpage>845</fpage>â<lpage>67</lpage>.<pub-id pub-id-type="pmid">12488461</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0023">
<string-name>
<surname>Zha</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>E</given-names>
</string-name>, <italic>et al</italic>
<article-title>Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14â3â3 not BCLâX(L)</article-title>. <source>Cell</source>. <year>1996</year>; <volume>87</volume>: <fpage>619</fpage>â<lpage>28</lpage>.<pub-id pub-id-type="pmid">8929531</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0024">
<string-name>
<surname>Ballif</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Blenis</surname>
<given-names>J</given-names>
</string-name>. <article-title>Molecular mechanisms mediating mammalian mitogenâactivated protein kinase (MAPK) kinase (MEK)âMAPK cell survival signals</article-title>. <source>Cell Growth Differ</source>. <year>2001</year>; <volume>12</volume>: <fpage>397</fpage>â<lpage>408</lpage>.<pub-id pub-id-type="pmid">11504705</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0025">
<string-name>
<surname>Hirano</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hibi</surname>
<given-names>M</given-names>
</string-name>. <article-title>Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the ILâ6 family of cytokine receptors</article-title>. <source>Oncogene</source>. <year>2000</year>; <volume>19</volume>: <fpage>2548</fpage>â<lpage>56</lpage>.<pub-id pub-id-type="pmid">10851053</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0026">
<string-name>
<surname>Bollen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Peti</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ragusa</surname>
<given-names>MJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>The extended PP1 toolkit: designed to create specificity</article-title>. <source>Trends Biochem Sci</source>. <year>2010</year>; <volume>35</volume>: <fpage>450</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">20399103</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0027">
<string-name>
<surname>Heroes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lesage</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Gornemann</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>The PP1 binding code: a molecularâlego strategy that governs specificity</article-title>. <source>FEBS J</source>. <year>2013</year>; <volume>280</volume>: <fpage>584</fpage>â<lpage>95</lpage>.<pub-id pub-id-type="pmid">22360570</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0028">
<string-name>
<surname>Diebold</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kraicun</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bonello</surname>
<given-names>S</given-names>
</string-name>, <italic>et al</italic>
<article-title>The âPAIâ1 paradoxâ in vascular remodeling</article-title>. <source>Thromb Haemost</source>. <year>2008</year>; <volume>100</volume>: <fpage>984</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">19132221</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0029">
<string-name>
<surname>Lademann</surname>
<given-names>UA</given-names>
</string-name>, <string-name>
<surname>Romer</surname>
<given-names>MU</given-names>
</string-name>. <article-title>Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAIâ1)</article-title>. <source>Thromb Haemost</source>. <year>2008</year>; <volume>100</volume>: <fpage>1041</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">19132228</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0030">
<string-name>
<surname>Balsara</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Ploplis</surname>
<given-names>VA</given-names>
</string-name>. <article-title>Plasminogen activator inhibitorâ1: the doubleâedged sword in apoptosis</article-title>. <source>Thromb Haemost</source>. <year>2008</year>; <volume>100</volume>: <fpage>1029</fpage>â<lpage>36</lpage>.<pub-id pub-id-type="pmid">19132226</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0031">
<string-name>
<surname>Chen</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>DO</given-names>
</string-name>, <string-name>
<surname>Reczek</surname>
<given-names>PR</given-names>
</string-name>, <italic>et al</italic>
<article-title>Plasminogen activator inhibitorâ1 inhibits prostate tumor growth through endothelial apoptosis</article-title>. <source>Mol Cancer Ther</source>. <year>2008</year>; <volume>7</volume>: <fpage>1227</fpage>â<lpage>36</lpage>.<pub-id pub-id-type="pmid">18483310</pub-id></mixed-citation>
      </ref>
      <ref id="jcmm13127-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="jcmm13127-cit-0032">
<string-name>
<surname>Bajou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Laug</surname>
<given-names>WE</given-names>
</string-name>, <italic>et al</italic>
<article-title>Plasminogen activator inhibitorâ1 protects endothelial cells from FasLâmediated apoptosis</article-title>. <source>Cancer Cell</source>. <year>2008</year>; <volume>14</volume>: <fpage>324</fpage>â<lpage>34</lpage>.<pub-id pub-id-type="pmid">18835034</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>